Safety and efficacy of growth-friendly instrumentation for early-onset scoliosis in patients with spinal muscular atrophy type 1 in the disease-modifying treatment era.

ABSTRACT:

Purpose

To evaluate the safety of growth-friendly instrumentation for early-onset scoliosis (EOS) in patients with spinal muscular atrophy (SMA) type 1 who received disease-modifying treatment (DMT) and analyze short-term efficacy.

Methods

Retrospective search was conducted between 2017 and 2023. Patients with genetically confirmed SMA type 1 who were surgically treated for spinal deformity and receiving DMTs (nusinersen, risdiplam, or onasemnogene abeparvovec) were included. SMA types 2 and 3 and patients who do not receive DMTs were excluded. Clinical and radiographic data were collected at preoperative, postoperative, and latest follow-up visits.

Results

Twenty-eight patients (mean follow-up: 16 months (range 2-41)) were included. The mean age at surgery was 60 mon

SUBMITTER: Cetik RM 

PROVIDER: S-EPMC10859117 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature